Skip to main content
Top
Published in: BMC Cancer 1/2020

Open Access 01-12-2020 | Metastasis | Research article

Modified nodal stage of esophageal cancer based on the evaluation of the hazard rate of the negative and positive lymph node

Authors: Jinling Zhang, Hongyan Li, Liangjian Zhou, Lianling Yu, Fengyuan Che, Xueyuan Heng

Published in: BMC Cancer | Issue 1/2020

Login to get access

Abstract

Background

The study aimed to propose a modified N stage of esophageal cancer (EC) on the basis of the number of positive lymph node (PLN) and the number of negative lymph node (NLN) simultaneously.

Method

Data from 13,491 patients with EC registered in the SEER database were reviewed. The parameters related to prognosis were investigated using a Cox proportional hazards regression model. A modified N stage was proposed based on the cut-off number of the re-adjusted ratio of the number of PLN (numberPLN) to the number of NLN (numberNLN), which were derived from the comparison of the hazard rate (HR) of numberPLN and numberNLN. The modified N stage was confirmed using the cross-validation method with the training and validation cohort, and it was also compared to the N stage from the American Joint Committee on Cancer (AJCC) staging system (7th edition) using Receiver Operating Characteristic (ROC) curve analysis.

Results

The numberPLN on prognosis was 1.042, while numberNLN was 0.968. The modified N stage was defined as follows: N1 stage: the ratio range was from 0 to 0.21; N2 stage: more than 0.21, but no more than 0.48; N3 stage: more than 0.48. The log-rank test indicated that significant survival differences were confirmed among the N1, N2 and N3 sub-groups of patients in the training population. The difference of all the patients using the modified N stage method were more significant than AJCC N stage. The result of ROC analysis indicated that the modified N stage could represent the N stage of EC more accurately.

Conclusion

The modified N stage based on the re-adjusted ratio of numberPLN to numberNLN can evaluate tumor stage more accurately than the traditional N stage.
Literature
1.
go back to reference Sohda M, Kuwano H. Current Status and Future prospects for esophageal Cancer treatment. Ann Thoracic Cardiovasc Surg. 2017;23:1–11.CrossRef Sohda M, Kuwano H. Current Status and Future prospects for esophageal Cancer treatment. Ann Thoracic Cardiovasc Surg. 2017;23:1–11.CrossRef
2.
go back to reference Rice TW, et al. Esophageal Cancer: associations with (pN+) lymph node metastases. Ann Surg. 2017;265:122–9.CrossRef Rice TW, et al. Esophageal Cancer: associations with (pN+) lymph node metastases. Ann Surg. 2017;265:122–9.CrossRef
3.
go back to reference Kajiyama Y. New Japanese classification of esophageal Cancer (11th edition). Gan To Kagaku Ryoho. 2016;43:1049–52.PubMed Kajiyama Y. New Japanese classification of esophageal Cancer (11th edition). Gan To Kagaku Ryoho. 2016;43:1049–52.PubMed
4.
go back to reference Oweira H, et al. Validation of the eighth clinical American joint committee on Cancer stage grouping for esophageal cancer. Future Oncol. 2018;14:65–75.CrossRef Oweira H, et al. Validation of the eighth clinical American joint committee on Cancer stage grouping for esophageal cancer. Future Oncol. 2018;14:65–75.CrossRef
5.
go back to reference Wu SG, et al. Sites of metastasis and overall survival in esophageal cancer: a population-based study. Cancer Manage Res. 2017;9:781–8. Wu SG, et al. Sites of metastasis and overall survival in esophageal cancer: a population-based study. Cancer Manage Res. 2017;9:781–8.
6.
go back to reference Chen J, et al. A new clinical staging system for esophageal cancer to predict survival after definitive chemoradiation or radiotherapy. Diseases of the esophagus: official journal of the international society for. Dis Esophagus. 2018;31(11):1–9. Chen J, et al. A new clinical staging system for esophageal cancer to predict survival after definitive chemoradiation or radiotherapy. Diseases of the esophagus: official journal of the international society for. Dis Esophagus. 2018;31(11):1–9.
7.
go back to reference Rice TW, et al. Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016;29:913–9. Rice TW, et al. Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016;29:913–9.
8.
go back to reference Kunisaki C, et al. Impact of lymph-node metastasis site in patients with thoracic esophageal cancer. J Surg Oncol. 2010;101:36–42.CrossRef Kunisaki C, et al. Impact of lymph-node metastasis site in patients with thoracic esophageal cancer. J Surg Oncol. 2010;101:36–42.CrossRef
9.
go back to reference Greenstein AJ, et al. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer. 2008;112(6):1239–46.CrossRef Greenstein AJ, et al. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer. 2008;112(6):1239–46.CrossRef
10.
go back to reference Hsu PK, et al. The prognostic value of the number of negative lymph nodes in esophageal cancer patients after transthoracic resection. Ann Thorac Surg. 2013;96(3):995–1001.CrossRef Hsu PK, et al. The prognostic value of the number of negative lymph nodes in esophageal cancer patients after transthoracic resection. Ann Thorac Surg. 2013;96(3):995–1001.CrossRef
11.
go back to reference Ma G, et al. A novel multivariate scoring system for determining the prognosis of lymph node-negative esophageal squamous cell carcinoma following surgical therapy: an observational study. Eur J Surg Oncol. 2015;41(4):541–7.CrossRef Ma G, et al. A novel multivariate scoring system for determining the prognosis of lymph node-negative esophageal squamous cell carcinoma following surgical therapy: an observational study. Eur J Surg Oncol. 2015;41(4):541–7.CrossRef
12.
go back to reference Hagens ERC, et al. The extent of lymphadenectomy in esophageal resection for cancer should be standardized. J Thorac Dis. 2017;9(S8):S713.CrossRef Hagens ERC, et al. The extent of lymphadenectomy in esophageal resection for cancer should be standardized. J Thorac Dis. 2017;9(S8):S713.CrossRef
13.
go back to reference Phillips AW, et al. Impact of extent of lymphadenectomy on survival, post Neoadjuvant chemotherapy and transthoracic Esophagectomy. Ann Surg. 2017;265(4):750–6.CrossRef Phillips AW, et al. Impact of extent of lymphadenectomy on survival, post Neoadjuvant chemotherapy and transthoracic Esophagectomy. Ann Surg. 2017;265(4):750–6.CrossRef
14.
go back to reference Yang HX, et al. An evaluation of the number of lymph nodes examined and survival for node-negative esophageal carcinoma: data from China. Ann Surg Oncol. 2010;17(7):1901–11.CrossRef Yang HX, et al. An evaluation of the number of lymph nodes examined and survival for node-negative esophageal carcinoma: data from China. Ann Surg Oncol. 2010;17(7):1901–11.CrossRef
15.
go back to reference Baba Y, et al. Negative lymph-node count is associated with survival in patients with resected esophageal squamous cell carcinoma. Surgery. 2013;153(2):234–41.CrossRef Baba Y, et al. Negative lymph-node count is associated with survival in patients with resected esophageal squamous cell carcinoma. Surgery. 2013;153(2):234–41.CrossRef
16.
go back to reference Dhar DK, et al. Appraisal of a revised lymph node classification system for esophageal squamous cell cancer. Ann Thorac Surg. 2007;83(4):1265–72.CrossRef Dhar DK, et al. Appraisal of a revised lymph node classification system for esophageal squamous cell cancer. Ann Thorac Surg. 2007;83(4):1265–72.CrossRef
17.
go back to reference Mariette C, et al. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008;247(2):365–71.CrossRef Mariette C, et al. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008;247(2):365–71.CrossRef
18.
go back to reference Bhamidipati CM, et al. Pathologic lymph node ratio is a predictor of survival in esophageal cancer. Ann Thorac Surg. 2012;94(5):1643–51.CrossRef Bhamidipati CM, et al. Pathologic lymph node ratio is a predictor of survival in esophageal cancer. Ann Thorac Surg. 2012;94(5):1643–51.CrossRef
19.
go back to reference Hsu WH, et al. The metastatic lymph node number and ratio are independent prognostic factors in esophageal cancer. J Gastrointest Surg. 2009;13(11):1913.CrossRef Hsu WH, et al. The metastatic lymph node number and ratio are independent prognostic factors in esophageal cancer. J Gastrointest Surg. 2009;13(11):1913.CrossRef
20.
go back to reference Feng J, Fau-Huang Y, et al. Prognostic analysis of esophageal cancer in elderly patients: metastatic lymph node ratio versus 2010 AJCC classification by lymph nodes. World J Surg Oncol. 2013;11:162.CrossRef Feng J, Fau-Huang Y, et al. Prognostic analysis of esophageal cancer in elderly patients: metastatic lymph node ratio versus 2010 AJCC classification by lymph nodes. World J Surg Oncol. 2013;11:162.CrossRef
21.
go back to reference He Z, et al. Use of the metastatic lymph node ratio to evaluate the prognosis of esophageal cancer patients with node metastasis following radical esophagectomy. PLoS One. 2013;8(9):e73446.CrossRef He Z, et al. Use of the metastatic lymph node ratio to evaluate the prognosis of esophageal cancer patients with node metastasis following radical esophagectomy. PLoS One. 2013;8(9):e73446.CrossRef
22.
go back to reference Tan Z, et al. Can lymph node ratio replace pn categories in the tumor-node-metastasis classification system for esophageal cancer? J Thorac Oncol. 2014;9(8):1214–21.CrossRef Tan Z, et al. Can lymph node ratio replace pn categories in the tumor-node-metastasis classification system for esophageal cancer? J Thorac Oncol. 2014;9(8):1214–21.CrossRef
23.
go back to reference Shao Y, et al. Assessment of lymph node ratio to replace the pN categories system of classification of the TNM system in esophageal squamous cell carcinoma. Journal of thoracic oncology: official publication of the International Association for the Study of. Lung Cancer. 2016;11(10):1774–84. Shao Y, et al. Assessment of lymph node ratio to replace the pN categories system of classification of the TNM system in esophageal squamous cell carcinoma. Journal of thoracic oncology: official publication of the International Association for the Study of. Lung Cancer. 2016;11(10):1774–84.
24.
go back to reference Akutsu Y, et al. The prevalence of overall and initial lymph node metastases in clinical T1N0 thoracic esophageal Cancer: from the results of JCOG0502, a prospective multicenter study. Ann Surg. 2016;264:1009–15.CrossRef Akutsu Y, et al. The prevalence of overall and initial lymph node metastases in clinical T1N0 thoracic esophageal Cancer: from the results of JCOG0502, a prospective multicenter study. Ann Surg. 2016;264:1009–15.CrossRef
25.
go back to reference Talsma K, et al. Impact of Neoadjuvant Chemoradiation on lymph node Status in esophageal Cancer: post hoc analysis of a randomized controlled trial. Ann Surg. 2017;266:e52–e3.CrossRef Talsma K, et al. Impact of Neoadjuvant Chemoradiation on lymph node Status in esophageal Cancer: post hoc analysis of a randomized controlled trial. Ann Surg. 2017;266:e52–e3.CrossRef
27.
go back to reference Miyata H, et al. Clinical outcome of Esophagectomy in elderly patients with and without Neoadjuvant therapy for thoracic esophageal Cancer. Ann Surg Oncol. 2015;22(3):794–801. Miyata H, et al. Clinical outcome of Esophagectomy in elderly patients with and without Neoadjuvant therapy for thoracic esophageal Cancer. Ann Surg Oncol. 2015;22(3):794–801.
28.
go back to reference Cheng J, et al. Explore the radiotherapeutic clinical target volume delineation for thoracic esophageal squamous cell carcinoma from the pattern of lymphatic metastases. J Thorac Oncol. 2013;8(3):359–65.CrossRef Cheng J, et al. Explore the radiotherapeutic clinical target volume delineation for thoracic esophageal squamous cell carcinoma from the pattern of lymphatic metastases. J Thorac Oncol. 2013;8(3):359–65.CrossRef
29.
go back to reference Rades D, et al. Predicting overall survival in patients with brain metastases from esophageal cancer. Anticancer Res. 2014;34(11):6763–5.PubMed Rades D, et al. Predicting overall survival in patients with brain metastases from esophageal cancer. Anticancer Res. 2014;34(11):6763–5.PubMed
Metadata
Title
Modified nodal stage of esophageal cancer based on the evaluation of the hazard rate of the negative and positive lymph node
Authors
Jinling Zhang
Hongyan Li
Liangjian Zhou
Lianling Yu
Fengyuan Che
Xueyuan Heng
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-07664-w

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine